Federal health authorities are sounding the alarm over a growing black market of counterfeit GLP-1 medications being sold across Canada, warning that fake versions of popular weight-loss drugs pose significant health risks to consumers.
GLP-1 medications — originally developed to regulate blood sugar in people with type 2 diabetes — have surged in popularity as weight-loss treatments. Brand-name products such as Ozempic, Rybelsus, and Wegovy now dominate much of Canada’s online advertising landscape.
However, federal officials report that counterfeit manufacturers are exploiting this demand by distributing unauthorized, fake versions of these drugs, often using forged branding and even falsified federal logos to mislead consumers.
A recent advisory from Health Canada warns that these off-market products may contain unknown or harmful substances. While some counterfeits could be inactive placebos, others may contain dangerous chemicals, incorrect dosages, or contaminants such as plastics, glass particles, bacteria, fungi, E. coli, or Salmonella.
According to federal officials, no confirmed hospitalizations or deaths linked to unauthorized GLP-1 products have been reported to date. However, regulators stress that the risks associated with counterfeit and unauthorized medications remain serious and unpredictable, particularly because the true contents of these products are unknown.
The popularity of GLP-1 medications, combined with high costs, is believed to be fueling the underground market. Authentic GLP-1 prescriptions in Canada can cost more than $500 per month, placing them out of reach for many consumers — especially amid ongoing cost-of-living pressures.
Industry experts suggest that high pricing and limited insurance coverage may be pushing some individuals toward cheaper, unauthorized alternatives found online. While physicians can prescribe GLP-1 medications when clinically appropriate, coverage often depends on insurer discretion, particularly when weight loss is perceived as cosmetic rather than medically necessary.
Health Canada also highlighted increasingly sophisticated tactics used by counterfeit sellers, including forging official letterhead and copying federal logos to make products appear legitimate. Authorities note that the majority of unauthorized GLP-1 sales appear to occur online rather than in physical stores, where oversight is typically stronger.
Experts believe pricing pressures may ease in the coming years when generic versions of GLP-1 drugs become available following patent expirations. Generic pharmaceuticals typically enter the market at substantially lower prices, sometimes reducing costs by as much as 50 percent. Some analysts anticipate that broader generic availability could emerge as early as late 2026.
In the meantime, federal regulators are urging Canadians to exercise extreme caution. Consumers are advised to verify Drug Identification Numbers (DINs) and ensure medications are purchased only from licensed pharmacies.
Health authorities warn that continued circulation of counterfeit GLP-1 medications presents a significant public health threat, emphasizing that stronger enforcement and consumer vigilance are essential to prevent potentially tragic outcomes.